COMP <GO>
VMD vs PGNY // REVENUE GROWTH (YOY)
Viemed Healthcare Inc. (NASDAQ) VS. Progyny Inc. (NASDAQ) • 15-METRIC TALLY: VMD 8
— PGNY 4
▲ REVENUE GROWTH (YOY) LEADER: VMD
LAST: $9.67 (-2.81%) • MKT CAP: $379.0M
revenue-growth
20.50%
LAST: $29.19 (+2.78%) • MKT CAP: $2.18B
revenue-growth
10.40%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VMD VS. PGNY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | VMD | PGNY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 57.50% | 23.60% | +33.90 | VMD | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 13.00% | 16.70% | -3.70 | PGNY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 6.6x | 20.5x | -13.90 | VMD | /valuation <GO> |
| Free Cash Flow Yield | 3.15% | 8.80% | -5.65 | PGNY | /fcf-yield <GO> |
| Operating Margin | 8.50% | 6.60% | +1.90 | VMD | /operating-margins <GO> |
| Net Profit Margin | 5.70% | 4.50% | +1.20 | VMD | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 20.50% | 10.40% | +10.10 | VMD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.59 | 8.84 | -2.25 | PGNY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | VMD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 60.0 | 55.1 | +4.90 | VMD | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 20.7x | 34.6x | -13.90 | VMD | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $379.0M | $2.18B | -$1.80B | PGNY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | VMD REV | PGNY REV | VMD GROSS % | PGNY GROSS % | VMD FCF | PGNY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $270.3M | $1.29B | 57.5% | 23.6% | $11.9M | $191.8M |
| FY 2024 | $224.3M | $1.17B | 59.4% | 21.7% | $1.3M | $173.7M |
| FY 2023 | $183.0M | $1.09B | — | — | $45.2M | $188.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VMD // BETA —
PGNY // BETA —